Canadian health authorities say they have diagnosed the first case of bird flu in a British Columbia woman who recently returned from China.» Read More
"Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.
A study says trillions of dollars could be saved in health-care billing and insurance administrative costs over the course of years.
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
The U.K.’s National Health Service, for decades a global case-study in universal healthcare, seems to be facing its biggest ever crisis of confidence.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.
Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.
Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.
Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders, and sickle cell anemia.
Brent Saunders, Actavis CEO, discusses the deal environment, the process of acquiring Allergan and the good that comes from activist investors.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
More and more Americans are "covered," but fewer and fewer Americans will actually be able to get health care, says Jake Novak. Here's why.
Get the best of CNBC in your inbox